| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.8 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.8 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | -0.0067 | 0.8 |
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | 0.0068 | 0.8 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | 0.0069 | 0.8 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | -0.0062 | 0.8 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.8 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.8 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.8 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.8 |